ResearcherFox Chase Cancer CenterActive in the last 2 years
Dany Barrak
Matched on ORCID iD 0000-0002-4900-0365; OpenAlex author ID A5000354322. Sources: OpenAlex.
Their work
- Papers
- 5
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 6
2022: 3 papers · 2023: none · 2024: 2 papers
Papers 5
- Type of neoadjuvant treatment strategy is associated with differential pathologic responses in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.amjsurg.2023.10.053↗
- Smoking history is associated with reduced efficacy of neoadjuvant therapy in pancreatic adenocarcinoma. Co-author DOI 10.1016/j.gassur.2024.01.007↗
- Total neoadjuvant therapy is associated with improved overall survival and pathologic response in pancreatic adenocarcinoma. Co-author DOI 10.1002/jso.26906↗
- Total neoadjuvant therapy for pancreatic adenocarcinoma increases probability for a complete pathologic response. Co-author DOI 10.1016/j.ejso.2021.12.473↗
- Total Neoadjuvant Treatment for Pancreatic Ductal Adenocarcinoma Is Associated With Limited Lymph Node Yield but Improved Ratio. Co-author DOI 10.1016/j.jss.2022.08.002↗
Closest collaborators
The 6 strongest of 6 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Sanjay S. Reddy · 5 shared papers, 2022–2024 · strength 1.01
- Paper Type of neoadjuvant treatment strategy is associated with differential pathologic responses in pancreatic ductal adenoc… DOI 10.1016/j.amjsurg.2023.10.053↗
- Paper Smoking history is associated with reduced efficacy of neoadjuvant therapy in pancreatic adenocarcinoma. DOI 10.1016/j.gassur.2024.01.007↗
- Paper Total neoadjuvant therapy is associated with improved overall survival and pathologic response in pancreatic adenocarci… DOI 10.1002/jso.26906↗
- Anthony M. Villano · 5 shared papers, 2022–2024 · strength 1.01
- Paper Type of neoadjuvant treatment strategy is associated with differential pathologic responses in pancreatic ductal adenoc… DOI 10.1016/j.amjsurg.2023.10.053↗
- Paper Smoking history is associated with reduced efficacy of neoadjuvant therapy in pancreatic adenocarcinoma. DOI 10.1016/j.gassur.2024.01.007↗
- Paper Total neoadjuvant therapy is associated with improved overall survival and pathologic response in pancreatic adenocarci… DOI 10.1002/jso.26906↗
- Rita C. Akumuo · 2 shared papers, 2024 · strength 0.50
- Paper Type of neoadjuvant treatment strategy is associated with differential pathologic responses in pancreatic ductal adenoc… DOI 10.1016/j.amjsurg.2023.10.053↗
- Paper Smoking history is associated with reduced efficacy of neoadjuvant therapy in pancreatic adenocarcinoma. DOI 10.1016/j.gassur.2024.01.007↗
- Eileen A. O’Halloran · 1 shared paper, 2022 · strength 0.17
- Maitham A. Moslim · 1 shared paper, 2022 · strength 0.17
- Neha Goel · 1 shared paper, 2022 · strength 0.17
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.